TruLive MedTech Honored with 2024 Global Medical Technology Innovation Award Amid IPO Filing

Jiangsu Trulive Medtech Co., Ltd. focuses on the field of cardiovascular diseases, which have extremely high mortality and disability rates and remain a gap in the domestically produced market in China. Its business comprehensively covers multiple interventional treatment areas such as heart valves, peripheral, and coronary interventions. It is a platform enterprise that has taken the lead in providing a one-stop innovative solution for blood flow management on a global scale. Relying on its strong research and development capabilities and a senior, complete operational team, Trulive Medtech has developed high-quality, proprietary medical devices with independent intellectual property rights and comprehensive solutions, filling the void in China’s high-end cardiovascular interventional medical device market. This provides Chinese doctors and patients with more advanced and diverse treatment options. Meanwhile, Trulive Medtech, based in China and strategically expanding globally, continuously upgrades through technological innovation and development. The company accelerates the expansion of its global commercial network, offering "Chinese solutions" and contributing "Chinese wisdom" to various niche markets in the cardiovascular intervention field that have long been monopolized by imported products.